November 18, 2025
Read the full article
11.13.2025
We are pleased to share that Prior Labs is collaborating with Oxford Cancer Analytics (OXcan) to apply TabPFN to high-clinical-need lung diseases, focusing on more accurate differentiation across complex disease stages.
Read more
1.9.2025
Oxford Cancer Analytics (OXcan), the medtech company developing blood tests for early cancer detection using advanced proteomics and AI, today announced it has raised US$11 million in Series A funding from global investors, including in-field institutional investors in disease detection and diagnostics. With the close of this round, Dr. Heinrich Roder, expert in lung cancer proteomics liquid biopsy, was appointed as Senior Vice President of Research and Development at OXcan.
Read more
1.10.2023
Oxford Cancer Analytics is pioneering a new generation of blood based liquid biopsy tests for early cancer detection, and has announced the completion of an additional seed financing round, led by Eka Ventures, with participation from LifeArc, MegaRobo Technologies, Oxford Technology Management, and value-add individual investors.
Read more
12.16.2022
The team from Oxford University Hospitals (OUH) NHS Foundation Trust, the Oxford Radcliffe Biobank and the local spin-out company Oxford Cancer Analytics (OXcan) will recruit 200 participants to identify cancer biomarkers - molecules such as proteins found in blood that are a sign of lung cancer.
Read more
For press enquiries, interviews and requests to re-use content, please contact us
%20(1).svg)